Advertisement

Topics

Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results

11:05 EDT 8 Aug 2017 | BioMedReports - Blog
  • Total Revenues of $200.5 Million Up 8 Percent
  • GAAP Diluted EPS was $0.19 and Adjusted EPS of $0.30
  • Record Hereditary Cancer Demand and 86 Percent of Revenue Under Long-Term Contract
  • Company Issues Fiscal Year 2018 and Fiscal First-Quarter 2018 Financial Guidance

SALT LAKE CITY, Aug. 08, 2017 (GLOBE NEWSWIRE)

Read more...

Original Article: Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results

NEXT ARTICLE

More From BioPortfolio on "Myriad Genetics Reports Fiscal Fourth-Quarter 2017 and Fiscal Full-Year 2017 Financial Results"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...